Protocol Ledger

NCT04939935 · Phase III · RECRUITING

Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

Interventional Phase III clinical trial protocol NCT04939935 sponsored by The University of Queensland in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-29 Enrollment: 1,174 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04939935
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,174 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04939935
Protocol FieldVerified Registry Value
NCT IdentifierNCT04939935
Consolidated Lead SponsorThe University of Queensland
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,174 participants (ESTIMATED)
Registered Start Date2022-11-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04939935
Hospital Research SiteLocationSite Profile
Royal Brisbane and Women's HospitalHerston, AustraliaOpen Hospital Dossier ->
Princess Alexandra HospitalWoolloongabba, AustraliaOpen Hospital Dossier ->
Royal Adelaide HospitalAdelaide, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI